The only way to convincingly prove aging is cured is to prove reversal in all 78 organs. To do this you need gold-standard non-biopsy based markers to measure biological age in every organ in every demographic adjusted for every confounder, at high accuracy and high reproducibility, all with good biostatistical methodology. Not to mention 100s of therapies, there is no evidence-based silver bullet on the horizon.

Simply relying on non-validated whole-body all-cause-mortality predictors such as GrimAge (the gold standard DNA methylation all cause mortality predictor), or poor markers of a single organ's biological age such as facial photo AI algorithms is a drop in the ocean (0.1%, i.e. 1 of 1000 biomarkers or 'clocks') of what is required to prove rejuvenation and cure of aging, or to guide clinical rejuvenation medicine practice at the N=1 level. Arguably, measuring DNAm over validated risk biomarkers or ageing clocks, or even at all in some contexts, could be considered clinical malpractice & pseudomedicine.

Clinicians lack understanding of longevity biomarker methodology & biostatistics - and often of therapies beyond semi-evidence based lifestyle interventions - as well as practically of how to solve medical data interoperability; whilst PhDs lack understanding of the realities & practicalities of the clinical medicine required to manage rejuvenation of all 78 organs.

The Longevity Escape Velocity Medicine (LEVMED) Specialty represents the most method agnostic and most comphrenesive possible evidence-based methodology for achieving Longevity Escape Velocity.

The LEVMED specialty constitutes many tools:

• Thousands of Aging Clocks: Thousands of demographic specific biological age regressions (multiple, non-linear and linear), via the Zolman Organ Biological Age Algorithm
• Next-gen Informed Consent: Consent that exceeds international patient decision aid standards (IPDAS)
• Evidence-based Therapies: The Longevity Level 1, 2, 3 protocol with Longevity Escape Velocity Medicine Clinical Guidelines 
• Evidence-based risk biomarkers: Zolman Optimal Clinical Outcomes (OCO) ranges for age-related disease clinical outcome risk biomarkers, 
• Evidence-based medicine grading: The modified Pyramid of Evidence for taking GRADE and N=1 experimentation into account
• Health data management: A Rejuvenation Electronic Health Record that solves all interoperability and biomarker methodology
• Training, clinical excellence and patient concordance: Longevity School Training for accreditation in Longevity Escape Velocity Medicine (LEVMED) for clinicians and patients
• Integrations of multiple or all aging clocks to master scores: The Zolman Age Reduction (ZAR) score to prove whole body, organ system, organ and sub-anatomical region specific rejuvenation, 
• Sharing, open-source & competition: as well as the Longevity Leaderboards and open-sourcing of all intervention methodologies and results data